FLT3 and acute myeloid leukemia: Among patients younger than 60 years, AML patients with UBTF-TD (n = 57) were significantly younger (median 36 years vs. 47 years; q-value <0.001), had lower BM blast infiltration (median 25% vs. 60%, q-value <0.001)and higher rates of WT1 mutations (63% vs. 8%, q-value <0.001), FLT3-ITDs (53% vs. 22%, q-value <0.001) and trisomy 8 (28% vs. 8%, q-value <0.001) compared to UBTF-wt AML patients in the ALFA-0702 study (Fig. 2B–D, Table 1, Supplementary Table 7).